Clinical Trial Progress and Application of Immune Checkpoint Inhibitors 
in the Treatment of Small Cell Lung Cancer

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors 
in the Treatment of Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the...

Full description

Bibliographic Details
Main Authors: Huiqiu ZHANG, Xiyang LI, Xichuan LI, Yanjun SU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
immunotherapy
immune checkpoint inhibitors
clinical trial progress
biomarkers
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.41

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.41

Similar Items